CSF3 and acute myeloid leukemia: The fact that AML samples from primary refractory patients showed a lower reduction in their clonogenic capacity after treatment with G-CSF supports the notion that the priming strategy with this agent should be more efficient in patients with a greater degree of chemosensitivity.